MED2005
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Erectile Dysfunction
Conditions
Erectile Dysfunction
Trial Timeline
Nov 1, 2018 → Jan 17, 2020
NCT ID
NCT03813992About MED2005
MED2005 is a phase 3 stage product being developed by Futura Medical for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT03813992. Target conditions include Erectile Dysfunction.
What happened to similar drugs?
11 of 20 similar drugs in Erectile Dysfunction were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03813992 | Phase 3 | Completed |
Competing Products
20 competing products in Erectile Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + placebo | Eli Lilly | Phase 3 | 40 |
| YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo | Yuhan | Phase 2 | 35 |
| Tacrolimus + Placebo | Astellas Pharma | Approved | 43 |
| Mirabegron | Astellas Pharma | Phase 1/2 | 32 |
| LY2452473 + Tadalafil + LY900010 | Eli Lilly | Phase 1 | 29 |
| tadalafil + placebo | Eli Lilly | Phase 3 | 40 |
| tadalafil | Eli Lilly | Phase 3 | 40 |
| LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473) | Eli Lilly | Phase 2 | 35 |
| Tadalafil | Eli Lilly | Approved | 43 |
| tadalafil + placebo | Eli Lilly | Approved | 43 |
| Tadalafil + Sildenafil Citrate | Eli Lilly | Approved | 43 |
| Tadalafil + Placebo | Eli Lilly | Phase 3 | 40 |
| Placebo + Tadalafil | Eli Lilly | Approved | 43 |
| Tadalafil + Placebo | Eli Lilly | Approved | 43 |
| tadalafil | Eli Lilly | Approved | 43 |
| Tadalafil + Sildenafil | Eli Lilly | Approved | 43 |
| tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)] | Eli Lilly | Phase 3 | 40 |
| Tadalafil + Placebo | Eli Lilly | Approved | 43 |
| Dapoxetine | Johnson & Johnson | Phase 3 | 40 |
| dapoxetine | Johnson & Johnson | Phase 3 | 40 |